Oncology Drugs

GT Biopharma secures FDA clearance for a Phase 1 trial of GTB-5550 in multiple myeloma, a strategic pivot for its TriKE® platform, but the trial's start hinges on securing grant funding.

Imvax has promising data and a clear regulatory path for its glioblastoma therapy. Now it faces the ultimate test: raising millions to fund the final push.

FDA Fast Track for Kestrel's KST-6051 signals more than just a new drug; it reveals a new strategy in the war on cancer, backed by Big Pharma's billions.

Promising trial data for a novel drug targets a stubborn lung cancer mutation, signaling a major strategic advance for BlossomHill Therapeutics and the oncology field.

TOLREMO's successful Phase I trial for TT125-802 validates a novel strategy against NSCLC, offering new hope by targeting cancer's clever escape routes.

Starton Therapeutics heads to a key investor conference not with a new molecule, but a new method. Can their delivery tech turn old drugs into new blockbusters?

Dr. Timothy Donahue's new leadership at Weill Cornell while on Trethera's board highlights a key trend: integrating top clinical minds to accelerate drug development.

As Aktis Oncology presents at key investor conferences, it showcases a precision miniprotein platform and a major Eli Lilly deal in a booming market.

Takeda's new rare blood cancer drug, MIMRYLO, partners with Onco360 in a strategic 'ultra-narrow' launch, signaling a major shift in patient care.

Alterome Therapeutics brings on a heavy-hitting CFO in Johanna Mylet, who guided Poseida to an IPO and Roche acquisition. What does this signal for its future?

Cipla and Qilu are teaming up to launch a biosimilar for Keytruda, the world's top cancer drug, signaling a major shift in patient access and market dynamics.

With a new cancer drug showing promise but cash reserves dwindling, Citius Pharma's CEO faces a critical test: convincing investors the pipeline is worth the risk.

The prestigious Prix Galien awards debut in Seoul, cementing South Korea's status as a life sciences leader and spotlighting a wave of homegrown innovation.

A biotech startup is targeting a hidden cause of chemo resistance. An AI firm claims it can predict a drug's success. Their deal is a major market signal.

As it launches a pivotal trial for its MYC inhibitor, Persevere Therapeutics adds a seasoned CEO to its board, signaling a sharp focus on funding and strategy.

BioLineRx secures crucial funds for its cancer drugs, but at a cost. We dissect the deal, the shareholder dilution, and what it reveals about biotech financing.

A new FDA approval for Roche's HER2 tests paves the way for a powerful new drug, offering hope to patients with aggressive gastroesophageal adenocarcinoma.

Avenzo Therapeutics' new CHRO hire is more than a personnel move; it's a critical piece of a master plan for a public debut and oncology market disruption.

PMV Pharma's rezatapopt shows remarkable results for a tough cancer by reactivating a key defense. A deep dive into the science, finances, and patient hope.

Fannin Partners secures key grants to advance its Raptamer therapy for a rare pediatric cancer, highlighting a funding model vital for high-risk innovation.